Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

CAMCEVI ETM

LEUPROLIDE MESYLATE

Standard Dose
EQ 21MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview CAMCEVI ETM is listed in Drugs@FDA under application 219745 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient LEUPROLIDE MESYLATE Form and strength EMULSION;SUBCUTANEOUS - EQ 21MG BASE Sponsor ACCORD Submission history Latest submission status date: 2025-08-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview CAMCEVI ETM is listed in Drugs@FDA under application 219745 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LEUPROLIDE MESYLATE Form and strength EMULSION;SUBCUTANEOUS - EQ 21MG BASE Sponsor ACCORD Submission history Latest submission status date: 2025-08-25 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.